 WOBURN, Mass., Oct. 06, 2021 GLOBE NEWSWIRE -- NeuroMetrix, Inc. Nasdaq: NURO today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration FDA for Quell as a prescription treatment for the symptoms of fibromyalgia in adults. The Company received FDA Breakthrough Designation for this indication in July. 